Literature DB >> 20501542

Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.

Christoph Rudin1, Marcel Wolbers, David Nadal, Martin Rickenbach, Heiner C Bucher.   

Abstract

AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children.
METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included.
RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children.
CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501542     DOI: 10.1136/adc.2009.169375

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  4 in total

1.  Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.

Authors:  Retsilisitsoe R Moholisa; Michael Schomaker; Louise Kuhn; Sandra Castel; Lubbe Wiesner; Ashraf Coovadia; Renate Strehlau; Faeezah Patel; Francoise Pinillos; Elaine J Abrams; Gary Maartens; Helen McIlleron
Journal:  Pediatr Infect Dis J       Date:  2016-12       Impact factor: 2.129

2.  Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.

Authors:  Torsak Bunupuradah; Thanyawee Puthanakit; Paul Fahey; Azar Kariminia; Nik K N Yusoff; Truong H Khanh; Annette H Sohn; Kulkanya Chokephaibulkit; Pagakrong Lumbiganon; Rawiwan Hansudewechakul; Kamarul Razali; Nia Kurniati; Bui V Huy; Tavitiya Sudjaritruk; Nagalingeswaran Kumarasamy; Siew M Fong; Vonthanak Saphonn; Jintanat Ananworanich
Journal:  Antivir Ther       Date:  2013-01-07

3.  Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

Authors:  Retsilisitsoe R Moholisa; Michael Schomaker; Louise Kuhn; Sandra Meredith; Lubbe Wiesner; Ashraf Coovadia; Renate Strehlau; Leigh Martens; Elaine J Abrams; Gary Maartens; Helen McIlleron
Journal:  Antivir Ther       Date:  2014-02-12

4.  HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  Int J Hepatol       Date:  2012-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.